Business Description
![BriaCell Therapeutics Corp BriaCell Therapeutics Corp logo](https://static.gurufocus.com/logos/0C00000ZF1.png?14)
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
STU:8BT: Ordinary Shares - NewCompare
Compare
Traded in other countries / regions
BCTX.USABCT.Canada8BT.Germany IPO Date
2016-04-05Description
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.66 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.9 | |||||
3-Year EPS without NRI Growth Rate | 37 | |||||
3-Year FCF Growth Rate | 5.7 | |||||
3-Year Book Growth Rate | 64.1 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.47 | |||||
9-Day RSI | 34.92 | |||||
14-Day RSI | 33.86 | |||||
6-1 Month Momentum % | -47.88 | |||||
12-1 Month Momentum % | -62.48 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.99 | |||||
Quick Ratio | 2.99 | |||||
Cash Ratio | 1.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -180.8 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -51.07 | |||||
ROIC % | -1505.61 | |||||
ROC (Joel Greenblatt) % | -841.45 | |||||
ROCE % | -114.04 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.75 | |||||
EV-to-Forward-EBIT | -0.4 | |||||
EV-to-EBITDA | -0.75 | |||||
EV-to-FCF | -0.62 | |||||
Earnings Yield (Greenblatt) % | -133.33 | |||||
FCF Yield % | -121.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.553 | ||
Beta | 1.33 | ||
Volatility % | 57.86 | ||
14-Day RSI | 33.86 | ||
14-Day ATR (€) | 0.079284 | ||
20-Day SMA (€) | 1.298 | ||
12-1 Month Momentum % | -62.48 | ||
52-Week Range (€) | 1.15 - 6.9 | ||
Shares Outstanding (Mil) | 18.28 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BriaCell Therapeutics Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(STU:8BT)'s stock price today?
The current price of STU:8BT is €1.22. The 52 week high of STU:8BT is €6.90 and 52 week low is €1.15.
When is next earnings date of BriaCell Therapeutics Corp(STU:8BT)?
The next earnings date of BriaCell Therapeutics Corp(STU:8BT) is 2024-06-14 Est..
Does BriaCell Therapeutics Corp(STU:8BT) pay dividends? If so, how much?
BriaCell Therapeutics Corp(STU:8BT) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |